Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+1-425-3987178
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Cocrystal Pharma (OTCMKTS:COCP) Frequently Asked Questions
What is Cocrystal Pharma's stock symbol?
Cocrystal Pharma trades on the OTCMKTS under the ticker symbol "COCP."
How were Cocrystal Pharma's earnings last quarter?
Cocrystal Pharma Inc (OTCMKTS:COCP) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $0.49 million for the quarter. View Cocrystal Pharma's Earnings History.
Has Cocrystal Pharma been receiving favorable news coverage?
News headlines about COCP stock have been trending somewhat positive on Wednesday, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cocrystal Pharma earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Cocrystal Pharma.
What other stocks do shareholders of Cocrystal Pharma own?
Who are Cocrystal Pharma's key executives?
Cocrystal Pharma's management team includes the folowing people:
- Raymond F. Schinazi Ph.D., Chairman of the Board (Age 65)
- Sam Lee, President (Age 56)
- Gary L. Wilcox Ph.D., Interim Chief Executive Officer, Vice Chairman of the Board (Age 69)
- James J. Martin, Chief Financial Officer (Age 50)
- David S. Block M.D., , Director (Age 56)
- Phillip Frost, Director (Age 79)
- Jane Hsiao Ph.D., M.B.A.,, Director (Age 68)
- Steven Rubin, Director (Age 55)
Who are Cocrystal Pharma's major shareholders?
Which major investors are buying Cocrystal Pharma stock?
How do I buy shares of Cocrystal Pharma?
Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cocrystal Pharma's stock price today?
One share of COCP stock can currently be purchased for approximately $1.77.
How big of a company is Cocrystal Pharma?
What is Cocrystal Pharma's official website?
How can I contact Cocrystal Pharma?
Cocrystal Pharma's mailing address is 1860 Montreal Rd, TUCKER, GA 30084-5709, United States. The company can be reached via phone at +1-425-3987178.
MarketBeat Community Rating for Cocrystal Pharma (OTCMKTS COCP)
MarketBeat's community ratings are surveys of what our community members think about Cocrystal Pharma and other stocks. Vote "Outperform" if you believe COCP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COCP will underperform the S&P 500 over the long term. You may vote once every thirty days.
